Effects of intravitreal injection of ranibizumab on intraocular pressure
Egyptian Journal of Hospital Medicine [The]. 2018; 73 (7): 7025-7031
Dans Anglais
| IMEMR
| ID: emr-202712
ABSTRACT
Background:
the administration of anti-vascular endothelial growth factor [anti-VEGF] agents has become an application of IVIs to treat a variety of retinal and choroidal neovascular diseases including neovascular age-related macular degeneration, vein occlusion with macular edema, and diabetic maculopathy. ranibizumab is the most commonly used anti-VEGF treatments for retinal disease. While Intravitreal ranibizumab appears to be safe and effective but it can cause adverse effects as intraocular inflammation, cataract, vitreous haemorrhage, and increased intraocular pressure
Recherche sur Google
Indice:
Méditerranée orientale
langue:
Anglais
Texte intégral:
Egypt. J. Hosp. Med.
Année:
2018
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS